Managing heart failure with immunomodulatory agents

Keyphrases

• Clinical Trials 50%
• Disease Progression 50%
• Etanercept 50%
• Heart Failure 100%
• Immune Activation 50%
• Immunosuppressive Agents 100%
• Inflammation 50%
• Operative 50%
• Randomized Clinical Trial 50%
• Symptomatic Heart Failure 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 33%
• Congestive Heart Failure 100%
• Disease Exacerbation 33%
• Etanercept 33%
• Immunotherapy 33%
• Inflammation 33%
• Randomized Clinical Trial 33%

Nursing and Health Professions

• Congestive Heart Failure 100%
• Disease Exacerbation 33%
• Etanercept 33%
• Immunotherapy 33%
• Inflammation 33%